Table 2. Diagnostic value of OPN in individual studies of these 13 eligible publications.
Studies | AUCs (95%CI) | Thresholds | Sensitivity | Specificity | TP | FP | FN | TN |
---|---|---|---|---|---|---|---|---|
Kim [22] | NR | 252 ng/ml | Early stage: 0.80 | 0.80 | 43 | 40 | 8 | 162 |
Late stage: 0.85 | ||||||||
Mor [23] | NR | NR | 0.80 | 0.76 | 80 | 25 | 20 | 81 |
Nakae [24] | NR | 489 ng/ml | 0.81 | 0.55 | 26 | 43 | 6 | 52 |
Meinhold-Heerlein [25] | NR | NR | 0.88 | 1.00 | 59 | 0 | 8 | 67 |
Moore [26] | 0.65(0.57–0.72) | NR | 0.20 | 0.90 | 13 | 17 | 54 | 149 |
Visintin [27] | 0.79(0.72–0.87) | NR | 0.73 | 0.70 | 114 | 107 | 42 | 255 |
Fredriksson [28] | NR | NR | 0.58 | 0.85 | 11 | 3 | 8 | 17 |
Vrzalova [29] | 0.804 | 2.91 ng/ml | 0.47 | 0.95 | 9 | 1 | 10 | 19 |
Lu [30] | NR | NR | 0.17 | 0.99 | 26 | 1 | 125 | 152 |
He [31] | 0.68 | NR | 0.65 | 0.66 | 24 | 5 | 13 | 10 |
Bandiera [32] | 0.92(0.87–0.97) | NR | 0.81 | 0.81 | 49 | 23 | 11 | 97 |
Moszynski [33] | 0.83(0.75–0.90) | 28.0 ng/ml | 0.72 | 0.89 | 23 | 9 | 9 | 73 |
Milivojevic [34] | 0.84(0.75–0.93) | 650 ng/ml | 0.63 | 0.90 | 30 | 3 | 18 | 28 |
NR, not reported;—, no data available; TP, true positive rate; FP, false-positive rate; FN, false-negative rate; TN, true negative rate.